

PRACTICAL ASEPTIC PROCESSING: FILL AND FINISH

VOLUME 1

CONTENTS

Preface	xi
<i>Irving J. Pflug</i>	
Introduction	xv
<i>Jack Lysfjord</i>	
Acknowledgements	vii
Dedication	xix
Glossary	xxi
 Part One: Current Global Influences on Aseptic Processing	
I Regulatory Background to Aseptic Processing	3
<i>Richard Johnson and Gordon Farquharson</i>	
Introduction	3
Global Regulatory Guidance	5
	iii

US FDA	5
EU Annex I	11
Canadian Regulation	14
Japanese Guidance	15
Other Useful References	16
Conclusion	17
About the Authors	17
2 Development Requirements of Biopharmaceutical Parenteral Dosage Forms	19
<i>John A. Bontempo</i>	
Key Requirements to Consider Before Preformulations and Formulations of Biopharmaceuticals Begin	20
Summary	32
References	32
About the Author	34
3 Biopharmaceutical Therapeutics Dosage Forms Delivery Systems and Current Status of Extractables and Leachables in Respective Parenteral Dosage Forms	35
<i>John A. Bontempo</i>	
Pre-filled Syringes	38
Auto-injectors	43
Pen Injector	45
Needle-free Injectors	46
Summary	46
Current Status of Extractables and Leachables in Respective Dosage Forms	46
What are Extractables and Leachables	47
Rigid Needle Shield	51
References	52
About the Author	53
4 Vaccines: Moving into the Future	55
<i>John Finkbohner</i>	
Introduction	55
Vaccines in the United States	56
Use of Vaccines in the U.S.	63
Overview of Immune Responses	63

Type of Vaccines	64
Challenges Facing the Modern Vaccine Business	66
Challenges of Vaccine Manufacturing	67
Formulation of Vaccines	71
Future Growth of Vaccines	74
Summary	76
References	77
About the Author	80

Part Two: Current Aseptic Processing Techniques

5 Container Preparation — Washing, Sterilization and Depyrogenation	85
<i>Johannes Rauschnabel, Patrizia Dittmer and Thomas Kosian</i>	
Container Cleaning	86
Sterilization and Depyrogenation with Dry Heat	93
References	103
About the Authors	103
6 Vial Processing — Accumulating, Conveying, Filling and Stoppering the Most Common Parenteral Container	105
<i>Alan Peterson</i>	
Introduction	105
Vial Infeed	107
Vial Transport — Intermittent Versus Continuous Motion	110
Overall Vial Transport Design	115
Vial Handling — Neck Vs. Bottom	117
Dosing Systems — Introduction	119
Product Contact	120
Filling Needles (Nozzles)	120
Product Considerations	122
Product Supply and Special Handling	123
CIP/SIP	125
Stoppering	125
Quality Control	131
Summary	133
About the Author	133

7	Checkweighing Fill Weight of Parenteral Product is the Heart of Process Quality	135
	<i>Alan Peterson</i>	
	Introduction	135
	Precision and Accuracy of Fill Volumes — Definitions and Statistical Analysis	136
	Checkweighing Methods	138
	Summary	144
	About the Author	144
8	Filling Methods as they Apply to Parenteral Product Quality and Biopharmaceutical Microdosing	145
	<i>Alan Peterson</i>	
	Introduction	145
	Time Pressure Filling	146
	Fill by Weight	149
	Mass Flow Filling	150
	Gravimetric Filling	153
	Peristaltic Pump Filling	156
	Piston Pumps	157
	Rolling Diaphragm Pump	161
	Microdosing	162
	Summary	165
	About the Author	165
9	Disposables — Single-Use Systems for Aseptic Processing and Filling Operations	167
	<i>Eric Isberg</i>	
	Background	167
	Use in Dosing Systems	170
	Materials of Construction	176
	Usage Considerations	177
	Materials Testing	178
	Sterility	179
	About the Author	180
10	Parenteral Non-Vial Container Formats — Ampoules, Syringes, Cartridges, Ophthalmics and IV Bags	181
	<i>Alan Peterson</i>	
	Introduction	181

Ampoules	182
Syringes	183
Bulk Glass Syringes	183
Syringe Filling and Stoppering	187
Cartridges	189
Nested Syringe Processing	189
Plastic Syringes	191
Ophthalmics — Plastic Bottles Dominate	193
IV Bags	195
Summary	195
About the Author	197
11 Application and Insights for Lyophilization of Parenteral Products	199
<i>Edward H. Trappler</i>	
Introduction	199
Applications of Lyophilization in Sterile Product Processing	201
Unique Requirements of Lyophilized Products	202
Characteristics of Lyophilized Parenterals	204
Processing Steps	205
Lyophilization Process Overview	205
Freezing	207
Primary Drying	209
Secondary Drying	209
Applications of Basic Principles	210
Methods of Analysis	211
Importance of the Phase Transition Temperature	211
Examples of Freeze Drying Cycles	213
Influences of Aseptic Process in Manufacturing	214
Process Control Parameters	215
Lyophilization Equipment	216
References	228
About the Author	229
12 Today's Integration of the Lyophilizer — Automated Loading and Unloading	231
<i>Ernesto Renzi</i>	
Introduction	231
History	233
Modern Loading/Unloading Systems	238
Flexible Loading Systems	239

Fixed Loading System	243
Freeze Dryers Designed for Loading Systems	250
Shelves	250
Freeze Dryer Chamber	252
Hydraulic Stoppering System	253
Equipment Layout	255
Conclusion	258
About the Author	259
13 Crimp Sealing Parenteral Vials	261
<i>F. William Bogle, Roger P. Asselta and Lawrence Pepper</i>	
Determining Percent Compression of Rubber Stoppers and Correlation to RSF in Parenteral Vials	263
Jaw Type Sealing	265
Spinning Roller Designs	267
Sealing Rail Cappers	269
Monitoring of Sealing Forces	269
Capping Environments	270
Alternatives	271
References	272
About the Authors	273
14 Inspection of Parenteral Products in Vials, Ampoules, Syringes and Cartridges	275
<i>Mike de la Montainge, Pedro J. Méndez and Ryosaku Tagaya</i>	
Introduction	275
Manual, Semi-Automated, and Automated Inspection Methods	276
Comparing the Quality, Economy and Efficiency of Inspection Methods	277
Visual (Human) Inspection Systems	278
Manual Inspection Systems	281
Semi-automated Visual Inspection Systems	281
Automated Inspection Systems	283
Reflected Light (Camera-Based) Automated Inspection Systems	283
Transmitted Light (Static Division) Automated Inspection Systems	284
Static Division System Operation	287
Static Divison Sensor	287
Sensing Capabilities	288
Conveyance of Containers	289

	Contents	ix
	Fill Level Check	290
	Camera-based Systems for Particulate and Cosmetic Inspection	290
	Typical Areas of Inspection by Container Type	294
	Validation of Automated Inspection Systems	296
	Visual Observation Tool	300
	Summary	301
	References	302
	About the Authors	304
15	New Inspection Developments	305
	<i>James Veale</i>	
	Introduction	305
	Nondestructive Headspace Analysis	207
	Regulatory Issues and Perspective	309
	Laser Technology for Rapid and Nondestructive Headspace Analysis	313
	Headspace Inspection Systems	321
	Aseptic Processing Applications	336
	Conclusion	369
	References	370
	About the Author	372
16	Practical Things to Improve Aseptic Process Equipment System Operation, Reduce Interventions and Reduce Product Risk	373
	<i>Jack Lysfjord</i>	
	About the Author	386
17	Dealing with the Complexities of Control Systems and Systems Integration	387
	<i>Terrance G. Petro</i>	
	Introduction	387
	Description of the Isolated Fill Line	387
	Boundaries of the System	389
	Overall Scope Definition	390
	Requirements of the System	392
	Control Room Selection	392
	Synchronization of Equipment	393
	SCADA Communication	394

Machine Specific Control Issues	395
General Control Issues	396
Conclusion	398
About the Author	398
Index	401

PRACTICAL ASEPTIC PROCESSING: FILL AND FINISH

VOLUME 1

PREFACE

Irving J. Pflug

The manufacturing isolator, as it is used in 2009, is the culmination of perhaps, 60 years of developments in the microbial control of the sterile products manufacturing environment.

Equipment developers Al Larson and Jack Lysfjord of TL Systems Corp. were forward-looking innovators, who in 1985 had a vision that they could install a manufacturing line in the already proven glove-box containment system. Working with Hans Melgaard of Despatch Industries Inc., an expert in HVAC and particulate control in air systems, they developed a system where containers were fed from a washer and continuous sterilization-depyrogenation tunnel directly into a fill finish isolator system where high efficiency particulate air (HEPA)-filtered air was used to pressurize the system.

The microbiology quality of injectible pharmaceutical products produced in the 1950s clean room was of continuous concern.

Knowledgeable operators recognized that the microbiological quality of the products produced in the 1950s clean room system was related to the human operators in the clean room — the human in the clean room was the source of the contamination. Control measures were taken, starting with gowns, hair coverings and masks, then a full bunny suit; however, the human was still in the clean room.

The leap forward in control was moving the barrier from the operator to the production line. Instead of putting coverings (bunny suit) on the individual and trying to contain the microorganisms within a bunny suit (to keep them from escaping to contaminate the manufacturing area), the barrier was placed around the production line with the human operator outside the enclosure or isolator. This was a positive, controllable approach to solving the problem of the microorganism shed by the human operators from contaminating the product being packaged.

The availability of air, essentially free of microbial contamination, is a critical component of the isolator system. Today the development of the HEPA filter, laminar/unidirectional flow clean room system is often taken for granted and assumed by the young to have always existed. This system was developed with the support of the National Aeronautical and Space Administration (NASA) for producing higher levels of quality in intricate space vehicles (basis for the important original U.S. Federal Standard 209 which has recently been superseded by ISO 14644), and is one of the more import and recent technological advances that has helped the pharmaceutical industry in many ways. The HEPA filtered clean air is a critical part of the manufacturing isolator system.

The isolator itself will prevent microbial ingress, however, a method of decontaminating the isolator is a basic requirement of the manufacturing isolator system. We have been able to sterilize biological material, media and hardware, primarily using saturated steam under pressure for 100 years. We have been using ethylene oxide (EO) for sterilization for 50 years. Neither of these agents is suited for the isolator. The isolator is a large enclosure, not readily suited for one atmosphere of over pressure, and it requires human operators to work intimately with the system. Hydrogen peroxide (H_2O_2), an old chemical with many important attributes, has become the sterilant of choice for the manufacturing isolator system. We are surprised that, in recent years, it has not received very much attention in the microbial-control area. The oxidizing capacity of H_2O_2 is so strong that the chemical is considered a highly reactive oxygen species. It is used extensively in the pulp and paper industry. The FDA has classified H_2O_2 a low regulatory priority (LRP) drug. A 3% solution is sold as an over-the-counter drug and is used for cleaning wounds and as an oral debriding agent.

Hydrogen peroxide is used to decontaminate the manufacturing isolator in an air- H_2O_2 system or in an atmospheric steam- H_2O_2 system. In the atmospheric steam- H_2O_2 system at 100.0°C, the kill of *Geobacillus stearothermophilis* spores is faster than in saturated steam at 15 psi pressure and 121.1°C.

The pharmaceutical manufacturing isolator is an engineering system which is capable of high production rates of products with both high quality level and at a unit cost not heretofore possible. As pharmaceutical products become more

potent and more hazardous to healthy individuals, operators must be protected from harmful agents. Isolators are one of the best engineering solutions for protecting both the product *and* operator. This represents a giant leap forward from the manufacturing systems in use only 20 years ago.

PRACTICAL ASEPTIC PROCESSING: FILL AND FINISH

VOLUME 1

INTRODUCTION

Jack Lysfjord

The seed for this book was planted in September 2005 at the PDA/FDA meeting in Washington D.C. Amy Davis, publisher of this book, and I were discussing how aseptic processing had changed since the mid 1990s.

Regulations have certainly changed with ISO 14644 cleanroom standards, 2004 FDA Aseptic Processing Guidelines, revision of Annex 1 of EU GMPs and International Council on Harmonization (ICH) working toward better global alignment of regulatory issues between countries.

Aseptic processing technology had changed with the use of Advanced Aseptic Processing techniques, such as blow/fill/seal (BFS), isolators and Restricted Access Barrier Systems (RABS). I believe that the product contamination rate can be improved from 1 contaminated unit out of 1,000 with conventional cleanroom processing to 1 out of 1,000,000 or even 1 out of 10,000,000 with the proper use of these advanced aseptic processing techniques. Conventional cleanroom processing has an inherent risk of human operators shedding of particles with viable micro-organisms into the containers.

Validation philosophy has evolved with the 5th edition of Good Automated Manufacturing Practices (GAMP 5). It is truly better understood today by industry as well as regulators. Process Analytical Technology (PAT), Quality by Design (QbD) with ICH Q8 (pharmaceutical development), Q9 (risk assessment) and Q10 (quality systems) tying things together for a better controlled process.

Products are changing with the increasing dominance of biologicals and biotech products including vaccines. Several large, well established pharmaceutical companies (over 100 years old) have now declared themselves to be “Biotech Companies”.

Today, more products are being produced that have a containment requirement, such as cytotoxics, to protect operators of process equipment and nurses who administer drugs to the patient.

Manufacturing of clinical trial material is a growing critical phase of aseptic processing as is the compounding of sterile preparations.

The rate of change is increasing rapidly. I felt as a contribution to newcomers to the industry, the seasoned person in operations, engineering or quality, pharmacists and regulators, that this book would draw a line in the sand for 2009 as to what is being done at this point in time. Current Good Manufacturing Practices (cGMP) are the current “state of the art”. We all need to stay on top of “what is current?”.

To limit the scope of this book, it will deal with manufacturing aseptic products until the container is closed, inspected and can be placed into “in process inventory” under quarantine. It will not deal with the downstream operations that involve “paper products” such as labeling, cartoning, casepacking etc.

I have worked hard to assemble a global group of authors for chapters that are experts in their particular topic to share their knowledge with you. I hope this information will be valuable for years to come.

Jack Lysfjord
Lysfjord Consulting LLC

PRACTICAL ASEPTIC PROCESSING: FILL AND FINISH

VOLUME 1

ACKNOWLEDGEMENTS

I want to thank my bride of 41 years, Pat, for sharing our life's journey together and putting up with my numerous travels and idiosyncrasies in corporate life and now as an independent consultant officing at home.

I also want to thank these people who come to mind. Who were and are mentors for life:

- Larry McGrath, with business, strategic vision, motivation, planning and weaving fun into work strengths
- Jerry Potter, with a “business nose”, sales skills and having fun while working philosophy
- Some of the TL Systems “Old Timers” from the good old days
 - Alan Peterson, Terry Petro, Dale Enwiller, Steve Braunschweig, Steve Swanson, Mike Beel, Ted Jagger, Carl Larson and Fred Nungesser
- The godfather of microbiology, Irving J. Pflug, for his wisdom and knowledge
- The drivers for what became the BUGS and LUMs groups
 - Irving J. Pflug, University of Minnesota, Allan Larson, president, TL Systems and Hans Melgaard, VP Technology, Despatch Industries

- Bob Best, president, ISPE who took on the idea of barriers and isolators
- Two pharmacists who help me see through their eyes:
 - Berthold Duethorn and Tom Jeatran
- Some of the regulators who helped advance the technology of aseptic processing:
 - Terry Munson, Ken Muhvich, Peter Cooney, Bob Sausville and Rick Friedman

Life is a journey. Enjoy it! Live your Bliss!

Jack Lysfjord

Minnetonka, Minnesota, March 10, 2009

PRACTICAL ASEPTIC PROCESSING: FILL AND FINISH

VOLUME 1

DEDICATION

I dedicate this book to the patients of the world! Everyone has been, is or will be a patient. I hope the contents of the book will positively influence the governments, regulators and the pharmaceutical and related industries to produce more, better, safer and more cost effective products to help patients lead a full productive life.

xix